UBS Group
DWTX

UBS Group’s Dogwood Therapeutics DWTX Stock Holding History

UBS Group’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9K Buy
7,085
+5,337
+305% +$15.7K ﹤0.01% 8141
2025
Q4 		$7.27K Buy
+1,748
New +$10.3K ﹤0.01% 8459
2025
Q2 		– Sell
-29,818
Closed -$149K – 11047
2025
Q1 		$149K Buy
29,818
+12,147
+69% +$82.2K ﹤0.01% 6746
2024
Q4 		$44K Buy
17,671
+10,229
+137% +$33.9K ﹤0.01% 7382
2024
Q3 		$31.6K Buy
7,442
+1,371
+23% +$7.11K ﹤0.01% 7103
2024
Q2 		$32.6K Buy
+6,071
New +$52.5K ﹤0.01% 7006
2024
Q1 		– Sell
-104
Closed -$1.5K – 10145
2023
Q4 		$1.5K Buy
+104
New +$1.75K ﹤0.01% 8291
2023
Q3 		– Sell
-11
Closed -$366 – 10065
2023
Q2 		$366 Sell
11
-54
-83% -$1.54K ﹤0.01% 8272
2023
Q1 		$600 Buy
+65
New +$517 ﹤0.01% 8964
2022
Q4 		– Sell
-1,642
Closed -$16K – 11234
2022
Q3 		$16K Buy
+1,642
New +$231K ﹤0.01% 7722
2022
Q2 		– Sell
-565
Closed -$63K – 11065
2022
Q1 		$63K Buy
565
+475
+528% +$69.1K ﹤0.01% 6267
2021
Q4 		$12K Buy
+90
New +$11.4K ﹤0.01% 8588
2021
Q3 		– Sell
-533
Closed -$84K – 10189
2021
Q2 		$84K Buy
+533
New +$75.6K ﹤0.01% 6021
2021
Q1 		– Sell
-133
Closed -$25K – 9567
2020
Q4 		$25K Buy
+133
New +$32.1K ﹤0.01% 6786

Other funds holding DWTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group's DWTX Position: Q1 2026 in Review

UBS Group increased its Dogwood Therapeutics (DWTX) stake by 305% in Q1 2026, buying an estimated $15.7K and bringing the position to 7,085 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #8141.

UBS Group first reported a position in DWTX in Q4 2020 and has held it in 14 quarters since. The position peaked at $149K in Q1 2025. 13 funds tracked by Wall St. Rank hold DWTX as of Q1 2026.

  • UBS Group held 7,085 shares of Dogwood Therapeutics worth $14.9K as of Q1 2026.
  • UBS Group bought 5,337 Dogwood Therapeutics shares in Q1 2026, an estimated $15.7K.
  • Dogwood Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8141 holding.
  • UBS Group first reported a position in Dogwood Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • UBS Group's Dogwood Therapeutics position peaked at $149K in Q1 2025.
  • 13 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.